After years of setbacks, there is renewed hope in the treatment of Alzheimer’s disease through the clearance of brain protein aggregates, despite limited success and potential side effects. The causes of Alzheimer’s are still not well understood, but early detection assays and research into viral infections as a contributing factor show promise. Addressing these factors with existing antiviral therapies could be key in finding more effective treatments for Alzheimer’s disease.
Alzheimer’s disease (AD) is a widespread neurodegenerative condition with limited treatment options. There has been significant progress in the development of monoclonal antibody (mAb) drugs targeting key players in AD pathogenesis, such as Aβ, tau, and neuroinflammation modulators. However, more research is needed to fully understand the clinical effects and mechanisms of action of these therapies, especially in later stages of the disease.
Link: https://doi.org/10.1016/j.arr.2024.102192
